The Asia Pacific oncology molecular diagnostics market was valued at $381.84 million in 2018 and is projected to reach $732.05 million by 2026, registering a CAGR of 9.0% from 2019 to 2026.
Molecular diagnostics is a set of cumulative techniques used for analyzing biological markers at molecular level such as genome and proteome. It is used for diagnosis and prediction of various infectious diseases, cancers, and other genetic disorders. Advancements in molecular diagnostics, including increased precision, faster turnarounds, and reduced costs act as key drivers for better genetic information.

The market is segmented on the basis of application, end user, and country. By application, it is categorized into lung, colorectal, breast, hematological, and others. By end user, it is segmented into hospitals, reference laboratories, and others (research institutes and academics). The hospitals segment was the highest contributor to the market, with $184.27 million in 2018, and is estimated to reach $354.46 million by 2026, at a CAGR of 9.0% during the forecast period.

Country wise, the market is divided into Australia, Vietnam, the Philippines, Thailand, and rest of Asia-Pacific. The oncology molecular diagnostics market growth, by country, is attributed to higher adoption and acceptance of personalized medicine, upgradation of healthcare infrastructure, and higher investments for R&D. Further, the market growth is attributed to increase in number of patients suffering from cancer in Asia-Pacific.

The key players profiled in this report include F. Hoffmann-La Roche AG, BioMerieux SA, Abbott Laboratories, Qiagen N.V., Sysmex, Danaher Corporation, S.A., Danaher, and Siemens Healthcare GmbH.

KEY BENEFITS FOR STAKEHOLDERS

u This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
u An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
u A comprehensive analysis of the factors that drive and restrain the growth of the Asia-Pacific oncology molecular diagnostics market is provided.
u An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Application
- Breast cancer
o By Technology
- PCR

- By Type
o Instruments
o Reagents
o Software & Services
- NGS
- By Type
o Instruments
o Reagents
o Software & Services
- Flow Cytometry

- By Type
o Instruments
o Reagents
o Software & Services
- FISH

- By Type
o Instruments
o Reagents
o Software & Services
- CISH

- By Type
o Instruments
o Reagents
o Software & Services
o
- Others

- By Type
o Instruments
o Reagents
o Software & Services
- Lung cancer
o By Technology
- PCR

- By Type
o Instruments
o Reagents
o Software & Services
- NGS

- By Type
o Instruments
o Reagents
o Software & Services
- Flow Cytometry
- By Type
o Instruments
o Reagents
o Software & Services
- FISH

- By Type
o Instruments
o Reagents
o Software & Services
- CISH

- By Type
o Instruments
o Reagents
o Software & Services
- Others

- By Type
o Instruments
o Reagents
o Software & Services
- Colorectal cancer
o By Technology
- PCR

- By Type
o Instruments
o Reagents
o Software & Services
- NGS

- By Type
o Instruments
o Reagents
o Software & Services
- Flow Cytometry

- By Type
o Instruments
o Reagents
o Software & Services
- FISH

- By Type
o Instruments
o Reagents
o Software & Services
- CISH

- By Type
o Instruments
o Reagents
o Software & Services
- Others

- By Type
o Instruments
o Reagents
o Software & Services

- Hematological cancer
o By Technology
- PCR

- By Type
o Instruments
o Reagents
o Software & Services
- NGS

- By Type
o Instruments
o Reagents
o Software & Services
- Flow Cytometry

- By Type
o Instruments
o Reagents
o Software & Services
- FISH

- By Type
o Instruments
o Reagents
o Software & Services
- CISH

- By Type
o Instruments
o Reagents
o Software & Services
- Others

- By Type
o Instruments
o Reagents
o Software & Services

- Others
o By Technology
- PCR

- By Type
o Instruments
o Reagents
o Software & Services
- NGS

- By Type
o Instruments
o Reagents
o Software & Services
- Flow Cytometry

- By Type
o Instruments
o Reagents
o Software & Services
- FISH

- By Type
o Instruments
o Reagents
o Software & Services
- CISH

- By Type
o Instruments
o Reagents
o Software & Services
- Others

- By Type
o Instruments
o Reagents
o Software & Services

- By End user
- Hospitals
- Reference Laboratories
- Others

- By Country
- Australia
- Thailand
- The Philippines
- Vietnam
- Rest of Asia-Pacific?

KEY MARKET PLAYERS
- F. Hoffmann-La Roche AG
- BioMerieux SA
- Abbott Laboratories
- Qiagen N.V.
- Sysmex Corporation
- Danaher Corporation, S.A.
- Siemens Healthcare GmbH.
- DiaSorin
- Illumina
- Agilent Technologies